Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108


CyberKnife for hilar lung tumors: report of clinical response and toxicity.

Unger K, Ju A, Oermann E, Suy S, Yu X, Vahdat S, Subramaniam D, Harter KW, Collins SP, Dritschilo A, Anderson E, Collins BT.

J Hematol Oncol. 2010 Oct 22;3:39. doi: 10.1186/1756-8722-3-39.


CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.

Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, Suy S, Yousefi S, Gutierrez CJ, Chang T, Banovac F, Anderson ED, Esposito G, Collins BT.

J Hematol Oncol. 2010 Feb 4;3:6. doi: 10.1186/1756-8722-3-6.


Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer.

Collins BT, Vahdat S, Erickson K, Collins SP, Suy S, Yu X, Zhang Y, Subramaniam D, Reichner CA, Sarikaya I, Esposito G, Yousefi S, Jamis-Dow C, Banovac F, Anderson ED.

J Hematol Oncol. 2009 Jan 17;2:1. doi: 10.1186/1756-8722-2-1.


CyberKnife radiosurgery for stage I lung cancer: results at 36 months.

Brown WT, Wu X, Fayad F, Fowler JF, Amendola BE, García S, Han H, de la Zerda A, Bossart E, Huang Z, Schwade JG.

Clin Lung Cancer. 2007 Sep;8(8):488-92.


Stereotactic body radiotherapy for central lung tumors.

Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH.

J Thorac Oncol. 2012 Sep;7(9):1394-9. doi: 10.1097/JTO.0b013e3182614bf3.


Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors.

Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu D, Whyte RI, Donington J.

J Thorac Oncol. 2006 Oct;1(8):802-9.


Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months.

Brown WT, Wu X, Fowler JF, García S, Fayad F, Amendola BE, de la Zerda A, Schwade JG.

South Med J. 2008 Apr;101(4):376-82. doi: 10.1097/SMJ.0b013e318167ad8d.


Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach.

Gill B, Oermann E, Ju A, Suy S, Yu X, Rabin J, Kalhorn C, Nair MN, Voyadzis JM, Unger K, Collins SP, Harter KW, Collins BT.

Front Oncol. 2012 Apr 26;2:39. doi: 10.3389/fonc.2012.00039. eCollection 2012.


CyberKnife with Tumor Tracking: An Effective Treatment for High-Risk Surgical Patients with Stage I Non-Small Cell Lung Cancer.

Chen VJ, Oermann E, Vahdat S, Rabin J, Suy S, Yu X, Collins SP, Subramaniam D, Banovac F, Anderson E, Collins BT.

Front Oncol. 2012 Feb 1;2:9. doi: 10.3389/fonc.2012.00009. eCollection 2012.


Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors.

Nishimura S, Takeda A, Sanuki N, Ishikura S, Oku Y, Aoki Y, Kunieda E, Shigematsu N.

J Thorac Oncol. 2014 Sep;9(9):1370-6. doi: 10.1097/JTO.0000000000000260.


Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.

Trakul N, Chang CN, Harris J, Chapman C, Rao A, Shen J, Quinlan-Davidson S, Filion EJ, Wakelee HA, Colevas AD, Whyte RI, Dieterich S, Maxim PG, Hristov D, Tran P, Le QT, Loo BW Jr, Diehn M.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):231-7. doi: 10.1016/j.ijrobp.2011.10.071. Epub 2012 Feb 28.


Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience.

Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22.


Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.

Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H.

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):126-35.


Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits.

Song DY, Benedict SH, Cardinale RM, Chung TD, Chang MG, Schmidt-Ullrich RK.

Am J Clin Oncol. 2005 Dec;28(6):591-6.


Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.

Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, Je HU, Park CI, Lee JS, Choi EK.

Lung Cancer. 2009 Oct;66(1):89-93. doi: 10.1016/j.lungcan.2008.12.016. Epub 2009 Jan 24.


Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.

Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V, Videtic GM.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):197-202. doi: 10.1016/j.ijrobp.2014.05.011. Epub 2014 Jul 8.


Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung.

Lee SW, Choi EK, Park HJ, Ahn SD, Kim JH, Kim KJ, Yoon SM, Kim YS, Yi BY.

Lung Cancer. 2003 Jun;40(3):309-15.


Application of robotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent.

Brown WT, Wu X, Fayad F, Fowler JF, García S, Monterroso MI, de la Zerda A, Schwade JG.

Clin Oncol (R Coll Radiol). 2009 Oct;21(8):623-31. doi: 10.1016/j.clon.2009.06.006. Epub 2009 Aug 13.


CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors.

Bhatnagar AK, Gerszten PC, Ozhasaglu C, Vogel WJ, Kalnicki S, Welch WC, Burton SA.

Technol Cancer Res Treat. 2005 Oct;4(5):571-6.


Stereotactic body radiation therapy for centrally located lung lesions.

Joyner M, Salter BJ, Papanikolaou N, Fuss M.

Acta Oncol. 2006;45(7):802-7.


Supplemental Content

Support Center